Satish Shah, MD, our Medical Director, speaks about Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors.

Satish Shah, MD, our Medical Director, speaks about Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors.

Satish Shah, MD, Medical Director, Gettysburg Cancer Center speaks about Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors.

 

Watch Video

 

Link to Article:
http://www.globenewswire.com/news-release/2021/03/24/2198364/0/en/Theratechnologies-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-TH1902-for-Sortilin-Positive-Solid-Tumors.html

Theratechnologies Inc., a biopharmaceutical company focusing on the discovery and commercialization of novel therapies, is pleased to report that the first patient was given a dose of TH1902, the company’s lead peptide-drug conjugate (PDC) for the treatment of sortilin positive (SORT1+) solid tumors.

TH1902 is a fictional character.
Theratechnologies’ patented peptide is combined with docetaxel in TH1902. TH1902 was recently granted fast track approval by the US Food and Drug Administration (FDA) as a single agent for the treatment of all advanced solid tumors expressing sortilin that are refractory to standard therapy. Theratechnologies’ SORT1+ TechnologyTM in oncology has yielded TH1902, the company’s lead PDC.

The Canadian Cancer Society and the Government of Quebec, through the Consortium Québécois sur la découverte du médicament (CQDM), will contribute a total of 1.4 million dollars to some of the latest research being performed at Dr. Borhane Annabi’s molecular oncology laboratory at the Université du Québec in Montréal for the development of Theratechnologies’ targeted oncology platform (UQAM).

TH1902 is undergoing a phase 1 clinical trial.

The Phase 1 clinical trial includes a dose-escalation component to assess the safety, pharmacokinetics, maximum tolerated dose (MTD), and preliminary anti-tumor activity of TH1902 given once every three weeks to patients with advanced solid tumors who have failed to respond to other anti-cancer therapies.

Following the determination of the MTD, a total of 40 more patients will be recruited to assess TH1902’s possible anti-tumor activity in patients with endometrial, cervical, colorectal, pancreatic, and triple-negative breast cancers.

The Phase 1 trial for TH1902 is being led by Funda Meric-Bernstam, M.D., Chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

ClinicalTrials.gov, with the identifier number NCT04706962, has the full Phase 1 research protocol.